LEBANON - Lebanon-based pharmaceutical manufacturer Penta Group announced that it has acquired the NerPharma facility in Milan, Italy, from NMS Group, a company specializing in oncology innovation, research, and development.

This strengthens Penta’s manufacturing footprint in Europe and expands its capabilities in producing oncology treatments, biologics, and high-potency medicines.

In a statement, Penta said the Italian plant is strategically located in one of Europe’s leading pharmaceutical hubs.

The facility employs more than 100 staff members and is certified by several regulatory authorities, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

The company added that the NerPharma plant provides comprehensive manufacturing capabilities for biologics and complex high-potency drugs, in addition to producing solid oral dosage forms and injectable medications.

It serves a range of local and international pharmaceutical clients and supports contract manufacturing operations.

Penta Chairman and CEO Bernard Tenouri described the acquisition as a major milestone in expanding the company’s European operations.